Praxis' essential tremor drug fails interim Phase 3 readout

Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price {$PRAX} down roughly 40%. The company was studying whether an experimental drug called ulixacaltamide could ...

Feb 28, 2025 - 16:33

Praxis' essential tremor drug fails interim Phase 3 readout

Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price {$PRAX} down roughly 40%. The company was studying whether an experimental drug called ulixacaltamide could ...